• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial Network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • US
    • INT
    • FR
Webinar: Tasly Pharmaceuticals and Mauna Kea Technologies Joint Venture

Webinar: Tasly Pharmaceuticals and Mauna Kea Technologies Joint Venture

by Zina | Jul 11, 2022 | Events

The Company’s management shared more information about the Tasly Pharmaceuticals and Mauna Kea Technologies Joint Venture: 
Webinar: Tasly Pharmaceuticals and Mauna Kea Technologies Joint Venture

Tasly Pharmaceuticals and Mauna Kea Technologies Announce Joint Venture and Licensing Agreements

by Zina | Jul 11, 2022 | News

Mauna Kea to form Joint Venture (JV) with Tasly to develop, manufacture and commercialize Cellvizio for the Chinese market. JV also to acquire exclusive worldwide rights to develop and commercialize Cellvizio in the fields of Neurology and Neurosurgery Subject to...
Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer

Mauna Kea Technologies Announces Publication of a Meta-Analysis Demonstrating Cellvizio’s Significant Role in Detection of Esophageal Dysplasia and Cancer

by Zina | Jul 6, 2022 | News

Results demonstrate a significant increase in the detection rate of neoplasia when Cellvizio is used as an adjunct to the standard of care, underscoring the key role of advanced imaging in slowing the rapid growth of esophageal cancer Meta-analysis builds on recent...
Giving physicians the power of precision imaging for lung disease

Giving physicians the power of precision imaging for lung disease

by Zina | May 24, 2022 | Press Coverage

Confocal laser endomicroscopy is an imaging technology that delivers visibility into cellular activity that enables physicians to assess areas of concern in cases where conventional disease screening returns ambiguous results.Read the complete article
Imaging Approach Helps To Detect Lung Cancer Earlier

Imaging Approach Helps To Detect Lung Cancer Earlier

by Zina | May 19, 2022 | Press Coverage

Researchers at the Abramson Cancer Center at the University of Pennsylvania  have found a way to identify lung cancer at the cellular level in real time during a biopsy, offering promise in the ability to detect the disease earlier and with more...
« Older Entries
Next Entries »

Articles récents

  • Mauna Kea Technologies Announces Largest Annual Pancreatic Cyst Consortium at Digestive Disease Week® 2025 
  • Publication of the 2024 Annual Financial Report 
  • Digestive Disease Week 2025
  • Mauna Kea Technologies Announces Another Milestone Year at Digestive Disease Week® 2025 with 8 Presentations Demonstrating the Clinical Value of Cellvizio® in Key Indications 
  • Mauna Kea Technologies Reports Full Year 2024 Results and Provides a Business Update 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}